Direct renin inhibitor/diuretic combo gets FDA nod
Aliskiren and hydrochlorothiazide combination approved
Combination antihypertensive, Tekturna HCT, has been approved by the FDA and contains both direct renin inhibitor aliskiren (Tekturna, Novartis) and diuretic hydrochlorothiazide in a single tablet. The approval was based on results of clinical trials involving more than 2,700 patients. According to the manufacturer, in one study evaluating rebound hypertension, the antihypertensive effect of Tekturna HCT was maintained for up to four days after the drug was discontinued, with blood pressure gradually returning to baseline. The new combination tablet will be available at wholesalers by early February and will be marketed in four strengths (aliskiren/HCTZ): 150 mg/12.5 mg, 150 mg/25 mg, 300 mg/12.5 mg, and 300 mg/25 mg. More information is available online at
Targeted Drug Combination Reveals New Activity in Brain Tumors
December 28th 2021A combination of two targeted cancer drugs showed unprecedented, “clinically meaningful” activity in patients with highly malignant brain tumors that carried a rare genetic mutation, according to a clinical trial report by investigators from Dana-Farber Cancer Institute.
